A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Summary

This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.

Timeline

Start

2019-05-24

Primary completion

2020-06-17

Completion

2020-06-17

Outcome

Outcome not reported

Stopped (Business): “Terminated due to sponsor decision.”

Drugs

Indications